Altimmune (ALT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist

9.490
+2.140+29.12%

Close Nov 12 16:00 ET

9.950
+0.460+4.85%

Post 19:05 ET

674.97MMarket Cap-6044P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Altimmune | 10-Q: Quarterly report
SEC16:13 ET · Announcements
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Benzinga14:27 ET
Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26.
Benzinga14:03 ET
Express News | Altimmune Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results. Also, UBS Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $26
Benzinga14:03 ET
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga13:44 ET
Altimmune Appoints Gregory Weaver as CFO for Growth
TipRanksNov 12 10:23 ET

Comments

Xyno

Nov 11 04:33

Partner or BO

$Altimmune (ALT.US)$ Exciting times ..! In a market forecasted to be 100 billion by 2030, Altimmune phase 2 results are very promising going into phase 3 trials.
Will a partner be announced or are the rumours true a buy out is eminent..!

frogoracletrading

Nov 7 08:33

$ALT Support / Resistance Levels

Here are the levels to watch on this push up.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

Jaguar8

Nov 7 07:02

NEWS

$Altimmune (ALT.US)$
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Altimmune (Nasdaq: ALT) announced successful completion of End-of-Phase 2 Meeting with FDA for pemvidutide in obesity treatment. The company received agreement on Phase 3 registrational program design, which will include four Phase 3 trials (VELOCITY-1,2,3,4) enrolling approximately 5,000 subjects over 60-week periods. The trials will evaluate pemvidut...